The FDA postponed until January a decision on whether to allow Pfizer's vaccine Prevnar 13 to be used in people age 50 and older. The vaccine is administered to protect younger children against pneumococcal disease.
Published in Brief:
|Vice President of Regulatory Affairs||
|Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX||
|Santa Clara, CA|
|Senior Director, Biostatistics||